Tadalafil Tablet, Film Coated
Product Images NDC 68071-5202

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 68071-5202). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 5202 3)

Label for Tadalafil 5 mg film-coated tablets by NuCare Pharmaceuticals, Inc. The label indicates a package of 30 tablets with NDC 68071-5202-3. It includes manufacturer information, barcode, and standard warnings such as 'Keep out of reach of children' and storage instructions at controlled room temperature (59-86°F). The label also displays multiple lot and serial numbers along with a QR code for product tracking.*

FDA Label Image

Figure (Tadalafil Figure1)

Four line graphs displaying the difference in blood pressure (systolic and diastolic, standing and supine) between tadalafil and placebo over time (0 to 96 hours). Each graph shows mean changes with error bars indicating variability across the time points.*

FDA Label Image

Figure (Tadalafil Figure2)

Two line graphs showing the effect of Tadalafil 20 mg with doxazosin 8 mg versus placebo with doxazosin 8 mg on systolic blood pressure. The top graph plots standing systolic blood pressure (mmHg) over time post-dose (hours), and the bottom graph plots supine systolic blood pressure (mmHg) over the same period. Both graphs show blood pressure changes for each treatment group as separate lines with markers.*

FDA Label Image

Figure (Tadalafil Figure3)

Line graph showing changes in systolic blood pressure (mmHg) over 12 hours after administration of tadalafil or placebo, with and without doxazosin. The x-axis represents time after administration in hours; the y-axis measures systolic blood pressure changes. Four lines differentiate treatment regimens: 20 mg tadalafil with 8 mg doxazosin at 08:00 and 20:00, and placebo with 8 mg doxazosin at 08:00 and 20:00.*

FDA Label Image

Figure (Tadalafil Figure4)

A line graph showing plasma tadalafil concentration (µg/L) over time (hours) for three dosing regimens: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dose after 5 days. The graph includes error bars representing variability at each time point and illustrates concentration changes up to 120 hours.*

FDA Label Image

Figure 5 (Tadalafil Figure5)

A line graph showing change from baseline in IPSS Total Score over 12 weeks comparing tadalafil 5 mg and placebo groups. The x-axis represents duration of treatment (weeks), and the y-axis shows change from baseline scores. The tadalafil group shows a greater decrease in score over time compared to placebo, with statistical significance noted at 12 weeks (p<0.01).*

FDA Label Image

Figure 6 (Tadalafil Figure6)

A line graph showing the change from baseline in IPSS total score over 12 weeks of treatment comparing tadalafil 5 mg and placebo. The horizontal axis represents treatment duration in weeks, while the vertical axis shows the change in IPSS score. The graph includes markers for statistically significant differences (* p<0.01) between tadalafil and placebo groups at multiple time points.*

FDA Label Image

Figure 7 (Tadalafil Figure7)

A line graph depicting the least squares mean change from baseline over weeks of therapy for Tadalafil/Finasteride and Placebo/Finasteride groups. The x-axis represents weeks of therapy (0, 4, 12, 26), while the y-axis shows the LS mean change from baseline. Tadalafil/Finasteride shows a greater negative change compared to Placebo/Finasteride, with statistical significance indicated at certain points (p<0.001, p<0.05).*

FDA Label Image

Figure 8 (Tadalafil Figure8)

A line graph comparing change from baseline in IPSS total score over a 12-week treatment duration for tadalafil 5 mg versus placebo. The graph shows decreases in scores for both groups over time, with tadalafil 5 mg consistently demonstrating a greater reduction. Data points are marked at 0, 2, 4, 8, and 12 weeks, with a statistically significant difference (p<0.01) noted at 12 weeks.*

FDA Label Image

Chemical Structure (Tadalafil Structure)

Chemical structure diagram of Tadalafil showing its molecular composition and arrangement of rings, nitrogen, oxygen, and carbon atoms consistent with the active pharmaceutical ingredient Tadalafil.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.